Rybelsus® (semaglutide) – New drug approval
September 20, 2019 - The FDA announced the approval of Novo Nordisk’s Rybelsus (semaglutide), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Download PDF
